195 related articles for article (PubMed ID: 22696596)
21. Matrix-remodeling associated 5 as a novel tissue biomarker predicts poor prognosis in non-small cell lung cancers.
He Y; Chen X; Liu H; Xiao H; Kwapong WR; Mei J
Cancer Biomark; 2015; 15(5):645-51. PubMed ID: 26406953
[TBL] [Abstract][Full Text] [Related]
22. Spectrum of EGFR gene mutations in Vietnamese patients with non-small cell lung cancer.
Vu HA; Xinh PT; Ha HT; Hanh NT; Bach ND; Thao DT; Dat NQ; Trung NS
Asia Pac J Clin Oncol; 2016 Mar; 12(1):86-90. PubMed ID: 26707566
[TBL] [Abstract][Full Text] [Related]
23. Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer.
Zhang LL; Kan M; Zhang MM; Yu SS; Xie HJ; Gu ZH; Wang HN; Zhao SX; Zhou GB; Song HD; Zheng CX
Int J Cancer; 2017 Jan; 140(1):103-108. PubMed ID: 27646734
[TBL] [Abstract][Full Text] [Related]
24. Mutation Spectrum of
Mao L; Zhao W; Li X; Zhang S; Zhou C; Zhou D; Ou X; Xu Y; Tang Y; Ou X; Hu C; Ding X; Luo P; Yu S
Pathol Oncol Res; 2021; 27():602726. PubMed ID: 34257561
[TBL] [Abstract][Full Text] [Related]
25. Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).
Lim SM; Kim HR; Cho EK; Min YJ; Ahn JS; Ahn MJ; Park K; Cho BC; Lee JH; Jeong HC; Kim EK; Kim JH
Oncotarget; 2016 Jun; 7(24):36311-36320. PubMed ID: 27121209
[TBL] [Abstract][Full Text] [Related]
26. EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases.
Luo D; Ye X; Hu Z; Peng K; Song Y; Yin X; Zhu G; Ji Q; Peng Y
Tumour Biol; 2014 Mar; 35(3):2437-44. PubMed ID: 24197981
[TBL] [Abstract][Full Text] [Related]
27. EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.
Wang Z; Wu YL; Zhang GC; Zhou Q; Xu CR; Guo AL
Onkologie; 2008 Apr; 31(4):174-8. PubMed ID: 18418018
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.
Li Y; Li Y; Yang T; Wei S; Wang J; Wang M; Wang Y; Zhou Q; Liu H; Chen J
PLoS One; 2013; 8(1):e52093. PubMed ID: 23341890
[TBL] [Abstract][Full Text] [Related]
29. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.
Scheffler M; Bos M; Gardizi M; König K; Michels S; Fassunke J; Heydt C; Künstlinger H; Ihle M; Ueckeroth F; Albus K; Serke M; Gerigk U; Schulte W; Töpelt K; Nogova L; Zander T; Engel-Riedel W; Stoelben E; Ko YD; Randerath W; Kaminsky B; Panse J; Becker C; Hellmich M; Merkelbach-Bruse S; Heukamp LC; Büttner R; Wolf J
Oncotarget; 2015 Jan; 6(2):1315-26. PubMed ID: 25473901
[TBL] [Abstract][Full Text] [Related]
30. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
Wang L; Hu H; Pan Y; Wang R; Li Y; Shen L; Yu Y; Li H; Cai D; Sun Y; Chen H
PLoS One; 2014; 9(2):e88291. PubMed ID: 24533074
[TBL] [Abstract][Full Text] [Related]
31. Mutation profile of non-small cell lung cancer revealed by next generation sequencing.
Chang YS; Tu SJ; Chen YC; Liu TY; Lee YT; Yen JC; Fang HY; Chang JG
Respir Res; 2021 Jan; 22(1):3. PubMed ID: 33407425
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer.
Cai L; Bai H; Duan J; Wang Z; Gao S; Wang D; Wang S; Jiang J; Han J; Tian Y; Zhang X; Ye H; Li M; Huang B; He J; Wang J
J Immunother Cancer; 2019 Jul; 7(1):198. PubMed ID: 31349879
[TBL] [Abstract][Full Text] [Related]
33. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.
Choi M; Kadara H; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Kim K; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Herbst RS; Wistuba II
Ann Oncol; 2017 Jan; 28(1):83-89. PubMed ID: 28177435
[TBL] [Abstract][Full Text] [Related]
34. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.
Jin G; Kim MJ; Jeon HS; Choi JE; Kim DS; Lee EB; Cha SI; Yoon GS; Kim CH; Jung TH; Park JY
Lung Cancer; 2010 Sep; 69(3):279-83. PubMed ID: 20018398
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients.
Liu L; Liu J; Shao D; Deng Q; Tang H; Liu Z; Chen X; Guo F; Lin Y; Mao M; Kristiansen K; Ye M; He J
Cancer Sci; 2017 Dec; 108(12):2487-2494. PubMed ID: 28949084
[TBL] [Abstract][Full Text] [Related]
36. Frequent TP53 gene alterations (mutation, allelic loss, nuclear accumulation) in primary non-small cell lung cancer.
Shipman R; Schraml P; Colombi M; Raefle G; Dalquen P; Ludwig C
Eur J Cancer; 1996 Feb; 32A(2):335-41. PubMed ID: 8664051
[TBL] [Abstract][Full Text] [Related]
37. Clinical Significance and Next-Generation Sequencing of Chinese Pulmonary Sarcomatoid Carcinoma.
Li X; Wang D; Zhao Q; Ren D; Ren F; Chen G; Liu H; Chen J
Sci Rep; 2017 Jun; 7(1):3947. PubMed ID: 28638113
[TBL] [Abstract][Full Text] [Related]
38. Molecular genetics of small cell lung carcinoma.
Wistuba II; Gazdar AF; Minna JD
Semin Oncol; 2001 Apr; 28(2 Suppl 4):3-13. PubMed ID: 11479891
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.
Bai H; Mao L; Wang HS; Zhao J; Yang L; An TT; Wang X; Duan CJ; Wu NM; Guo ZQ; Liu YX; Liu HN; Wang YY; Wang J
J Clin Oncol; 2009 Jun; 27(16):2653-9. PubMed ID: 19414683
[TBL] [Abstract][Full Text] [Related]
40. Validating a targeted next-generation sequencing assay and profiling somatic variants in Chinese non-small cell lung cancer patients.
Jiang R; Zhang B; Teng X; Hu P; Xu S; Zheng Z; Liu R; Tang T; Ye F
Sci Rep; 2020 Feb; 10(1):2070. PubMed ID: 32034196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]